|
1
|
Cowan AJ, Green DJ, Kwok M, Lee S, Coffey
DG, Holmberg LA, Tuazon S, Gopal AK and Libby EN: Diagnosis and
management of multiple myeloma: A review. JAMA. 327:464–477. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Global Burden of Disease Collaborative
Network. Global Burden of Disease Study 2022, . cancer incidence,
mortality, years of life lost, years lived with disability, and
disability-adjusted life years. Lancet Oncol. 23 (Suppl):S1–S100.
2023.
|
|
3
|
Kumar SK, Dispenzieri A, Lacy MQ, Gertz
MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, et
al: Continued improvement in survival in multiple myeloma: Changes
in early mortality and outcomes in older patients. Leukemia.
34:2885–2893. 2020.
|
|
4
|
Blimark C, Holmberg E, Mellqvist UH,
Landgren O, Bjorkholm M, Hultcrantz M, et al: Extramedullary
disease in multiple myeloma: Risk factors and outcome in the era of
novel agents. Haematologica. 100:457–464. 2015.PubMed/NCBI
|
|
5
|
Raje N, Berdeja J, Lin Y, Siegel D, Munshi
N, Lonial S, et al: Anti-BCMA CAR T-cell therapy bb2121 in relapsed
or refractory multiple myeloma: Updated results from a phase 1
trial. Blood. 134:9282019.
|
|
6
|
Gagelmann N, Riecken K, Wolschke C, Berger
C, Ayuk FA, Fehse B, et al: Extramedullary disease in multiple
myeloma: Challenges and future directions. Blood Cancer J. 12:1–10.
2022.
|
|
7
|
Zhao WH, Liu J, Wang BY, Chen YX, Cao XM,
Yang Y, et al: CAR-T cell therapy in relapsed/refractory multiple
myeloma with extramedullary disease: A Single-center retrospective
study. Front Immunol. 13:1–10. 2022.
|
|
8
|
Chinese Hematology Association, . Chinese
Society of Hematology, Chinese Myeloma Committee-Chinese Hematology
Association. The guidelines for the diagnosis and management of
multiple myeloma in China (2017 revision). Zhonghua Nei Ke Za Zhi.
56:866–870. 2017.(In Chinese). PubMed/NCBI
|
|
9
|
Durie BG and Salmon SE: A clinical staging
system for multiple myeloma. Correlation of measured myeloma cell
mass with presenting clinical features, response to treatment, and
survival. Cancer. 36:842–854. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Greipp PR, San Miguel J, Durie BG, Crowley
JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H,
Kyle RA, et al: International staging system for multiple myeloma.
J Clin Oncol. 23:3412–3420. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Palumbo A, Avet-Loiseau H, Oliva S,
Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S,
Lahuerta JJ, Facon T, et al: Revised international staging system
for multiple myeloma: A report from international myeloma working
group. J Clin Oncol. 33:2863–2869. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gonsalves WI, Buadi FK, Ailawadhi S,
Bergsagel PL, Chanan Khan AA, Dingli D, Dispenzieri A, Fonseca R,
Hayman SR, Kapoor P, et al: Utilization of hematopoietic stem cell
transplantation for the treatment of multiple myeloma: A mayo
stratification of myeloma and risk-adapted therapy (mSMART)
consensus statement. Bone Marrow Transplant. 54:353–367. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
National Comprehensive Cancer Network
(NCCN), . NCCN Guidelines Multiple Myeloma. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1445April
18–2024
|
|
14
|
Holstein SA, Grant SJ and Wildes TM:
Chimeric antigen receptor T-cell and bispecific antibody therapy in
multiple myeloma: Moving into the future. J Clin Oncol.
41:4416–4429. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bal S, Malek E, Kansagra A, Usmani SZ, Vij
R, Godby KN, Cornell RF, Kang Y, Umyarova E, Giri S, et al:
Treatment outcomes of triple class refractory multiple myeloma: A
benchmark for new therapies. Leukemia. 36:877–880. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mateos MV, Weisel K, De Stefano V,
Goldschmidt H, Delforge M, Mohty M, Cavo M, Vij R, Lindsey-Hill J,
Dytfeld D, et al: LocoMMotion: A prospective, noninterventional,
multinational study of real-life current standards of care in
patients with relapsed and/or refractory multiple myeloma.
Leukemia. 36:1371–1376. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gill SK, Unawane R, Wang S, Ahn J, Aleman
A, Siegel DS, Vesole DH, Parmar H, Phull P and Biran N: I-OPen:
Inferior outcomes of Penta-refractory compared to Penta-exposed
multiple myeloma patients. Blood Cancer J. 12:1382022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Goel U, Charalampous C, Kapoor P, Binder
M, Buadi FK, Dingli D, Dispenzieri A, Fonder A, Gertz MA, Gonsalves
WI, et al: Defining drug/drug class refractoriness vs lines of
therapy in relapsed/refractory multiple myeloma. Blood Cancer J.
13:112023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gandhi UH, Cornell RF, Lakshman A, Gahvari
ZJ, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S,
et al: Outcomes of patients with multiple myeloma refractory to
CD38-targeted monoclonal antibody therapy. Leukemia. 33:2266–2275.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Berdeja JG, Madduri D, Usmani SZ,
Jakubowiak A, Agha M, Cohen AD, Stewart AK, Hari P, Htut M,
Lesokhin A, et al: Ciltacabtagene autoleucel, a B-cell maturation
antigen-directed chimeric antigen receptor T-cell therapy in
patients with relapsed or refractory multiple myeloma
(CARTITUDE-1): A phase 1b/2 open-label study. Lancet. 398:314–324.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ri M, Suzuki K, Ishida T, Kuroda J,
Tsukamoto T, Teshima T, Goto H, Jackson CC, Sun H, Pacaud L, et al:
Ciltacabtagene autoleucel in patients with relapsed/refractory
multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort. Cancer
Sci. 113:4267–4276. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Munshi NC, Anderson LD Jr, Shah N, Madduri
D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, et al:
Idecabtagene vicleucel in relapsed and refractory multiple myeloma.
N Engl J Med. 384:705–716. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Minakata D, Ishida T, Ando K, Suzuki R,
Tanaka J, Hagiwara S, Ananthakrishnan R, Kuwayama S, Nishio M,
Kanda Y and Suzuki K: Phase 2 results of idecabtagene vicleucel
(ide-cel, bb2121) in Japanese patients with relapsed and refractory
multiple myeloma. Int J Hematol. 117:729–737. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sanoyan DA, Seipel K, Bacher U, Kronig MN,
Porret N, Wiedemann G, Daskalakis M and Pabst T: Real-life
experiences with CAR T-cell therapy with idecabtagene vicleucel
(ide-cel) for triple-class exposed relapsed/refractory multiple
myeloma patients. BMC Cancer. 23:3452023. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
IASO Biotherapeutics, . IASO Bio Presents
updated long-term follow-up data for BCMA CAR-T FUCASO®
(Equecabtagene Autoleucel) at IMS 2023. 2023.https://en.iasobio.com/info.php?id=225April
18–2024
|
|
26
|
Chen W, Fu C, Fang B, Liang A, Xia Z, He
Y, Lu J, Liu H, Hou M, Cai Z, et al: Phase II study of fully human
BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in patients
with relapsed/refractory multiple myeloma. Blood. 140
(Suppl):1:S4564–S4565. 2022. View Article : Google Scholar
|
|
27
|
Wang D, Wang J, Hu G, Wang W, Xiao Y, Cai
H, Jiang L, Meng L, Yang Y, Zhou X, et al: A phase 1 study of a
novel fully human BCMA-targeting CAR (CT103A) in patients with
relapsed/refractory multiple myeloma. Blood. 137:2890–2901. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
National Medical Products Administration
(NMPA), . Equecabtagene autoleucel injection approved with
conditions by China NMPA, 2023. https://english.nmpa.gov.cn/2023-06/30/c_940315.htmApril
19–2024
|
|
29
|
Rafiq S, Yeku OO, Jackson HJ, Purdon TJ,
van Leeuwen DG, Drakes DJ, Song M, Miele MM, Li Z, Wang P, et al:
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances
anti-tumor efficacy in vivo. Nat Biotechnol. 36:847–856. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zolov SN, Rietberg SP and Bonifant CL:
Programmed cell death protein 1 activation preferentially inhibits
CD28.CAR-T cells. Cytotherapy. 20:1259–1266. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yan Z, Cao J, Cheng H, Qiao J, Zhang H,
Wang Y, Shi M, Lan J, Fei X, Jin L, et al: A combination of
humanized anti-CD19 and anti-BCMA CAR T cells in patients with
relapsed or refractory multiple myeloma: A single-arm, phase 2
trial. Lancet Hematol. 6:e521–e529. 2019. View Article : Google Scholar
|
|
32
|
Rosiñol L, Beksac M, Zamagni E, Van de
Donk NWCJ, Anderson KC, Badros A, Caers J, Cavo M, Dimopoulos MA,
Dispenzieri A, et al: Expert review on soft-tissue plasmacytomas in
multiple myeloma: Definition, disease assessment and treatment
considerations. Br J Hematol. 194:496–507. 2021. View Article : Google Scholar
|
|
33
|
Cohen AD, Garfall AL, Stadtmauer EA,
Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K,
Nelson A, et al: B-cell maturation antigen-specific CAR T cells are
clinically active in multiple myeloma. J Clin Invest.
129:2210–2221. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu J, Chen LJ, Yang SS, Sun Y, Wu W, Liu
YF, Xu J, Zhuang Y, Zhang W, Weng XQ, et al: Exploratory trial of a
biepitopic CAR T-targeting B-cell maturation antigen in
relapsed/refractory multiple myeloma. Proc Natl Acad Sci USA.
116:9543–9551. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Raje N, Berdeja J, Lin Y, Siegel D,
Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A,
et al: Anti-BCMA CAR T-Cell therapy bb2121 in relapsed or
refractory multiple myeloma. N Engl J Med. 380:1726–1737. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li C, Cao W, Que Y, Wang Q, Xiao Y, Gu C,
Wang D, Wang J, Jiang L, Xu H, et al: A phase I study of anti-BCMA
CAR T-cell therapy in relapsed/refractory multiple myeloma and
plasma cell leukemia. Clin Transl Med. 11:e3462021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang M, Zhou L, Zhao H, Zhang Y, Wei G,
Hong R, Wu W, Xu H, Wang L, Ni F, et al: Risk factors associated
with durable progression-Free survival in patients with relapsed or
refractory multiple myeloma treated with Anti-BCMA CAR T-cell
therapy. Clin Cancer Res. 27:6384–6392. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li W, Liu M, Yuan T, Yan L, Cui R and Deng
Q: Efficacy and follow-up of humanized anti-BCMA CAR-T-cell therapy
in relapsed/refractory multiple myeloma patients with
extramedullary-extraosseous, extramedullary-bone related, and
without extramedullary disease. Hematol Oncol. 40:223–232. 2022.
View Article : Google Scholar : PubMed/NCBI
|
